source
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.Fierce Biotech · 14d ago↗ source
- Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaTakeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.BioSpace · 14d ago↗ source
- FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in HorsesThe FDA today issued an Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses (ivermectin oral solution) for the short-term prevention of New World screwworm (NWS) infestations (myiasi…